TriNetX is proud to announce that we were named a Best of Show Finalist at SCOPE, the summit for clinical ops executives, one of the industry’s premier events focused on advancing clinical operations and innovation. This recognition highlights our continued commitment to transforming how life sciences organizations plan, design, and execute clinical trials through data-driven intelligence.
This milestone builds on our recent recognition as a Best of Show Finalist at SCOPE Europe, reinforcing TriNetX’s momentum across global markets and underscoring the growing impact of our latest innovations. At both events, our work was recognized for pushing the boundaries of how real-world data (RWD) can be accessed, analyzed, and operationalized, directly within the systems and workflows our partners already use.
At the summit held February 2-5 in Orlando, Florida, TriNetX was recognized for our enhanced API capabilities with conversational AI integration, a significant evolution in how pharmaceutical companies interact with RWD for clinical trial planning and feasibility.
A New Era of Access to RWD
Clinical trial planning has long been constrained by technical barriers, data silos, and the need for specialized expertise to generate feasibility insights. TriNetX’s enhanced API capabilities are designed to address these challenges by enabling seamless, real-time access to high-quality RWD across our global network.
With this innovation, partners can send study queries, using either medical codes or plain-language questions, directly from their own systems into the TriNetX platform. These queries are executed in real time across TriNetX’s global network of 280+ million patients sourced from 230+ healthcare organizations. The platform returns patient counts, feasibility metrics, and site intelligence without requiring users to leave their existing workflows.
By embedding TriNetX insights directly into proprietary environments, these capabilities help research teams move faster, collaborate more effectively, and make more informed decisions earlier in the study lifecycle.
Conversational AI Meets Enterprise-Grade APIs
At the core of this innovation is the integration of a conversational AI interface with TriNetX’s enhanced API framework. Researchers can now ask complex feasibility and study design questions in natural language without needing deep query-building or technical expertise.
This approach broadens access to advanced RWD analytics across organizations. Clinical operations, study design, data science, and digital teams can all interact with the same underlying data using language that aligns with how they already think about research questions.
These conversational queries are powered by TriNetX’s proprietary clinical ontology, ensuring natural language inputs are translated into precise, structured queries. The data accessed through the API is sourced directly from TriNetX’s global provider network, which is continuously refreshed and fully traceable, supporting confidence and transparency in every insight delivered.
What’s New (and Why It Matters)
The enhanced API capabilities recognized at SCOPE represent more than incremental improvement. They reflect a meaningful shift in how RWD can support enterprise-wide clinical research strategies.
By reducing reliance on specialized technical skills and eliminating manual platform navigation, TriNetX is helping organizations:
- Break down data silos between teams and systems
- Accelerate feasibility assessments and protocol development
- Support enterprise-wide digital transformation initiatives
These capabilities also help pave the way toward agentic AI–level integration, bringing the industry closer to intelligent, autonomous, data-driven decision-making. As systems become more connected and capable of acting on insights in real time, the enhanced TriNetX API provides a strong foundation for what comes next.
Technical Capabilities Designed for Real-World Impact
These capabilities are supported by a robust set of technical features:
- Real-time federated query execution across the global TriNetX healthcare network
- Ability to create and edit queries from proprietary systems using medical codes or natural language
- Scheduled API runs for automated, recurring data refreshes
- Location-based patient counts at both healthcare organization and site levels
- Comprehensive site intelligence, including industry-standard identifiers and clinical trial experience
- Protocol optimization analytics to support refinement of inclusion and exclusion criteria
Together, these features enable teams to continuously assess feasibility, evaluate site options, and optimize protocols while staying within their preferred technology environments.
Looking Ahead
As we celebrate this SCOPE recognition, we remain focused on making it simple to use complex data, enabling life sciences organizations to design better studies, select the right sites, and move clinical research forward more efficiently.
We’re honored to stand alongside other innovators at SCOPE and are grateful to those who recognized the impact of our enhanced technological capabilities. We look forward to continuing this momentum and sharing updates as our platform evolves.
Ready to see what this looks like in action?
Join us on March 18 at 11 am ET for our webinar, Smarter Trial Decisions Through Clincal Data Integration. Building on the innovations recognized at SCOPE, experts will explore how integrated, interoperable data platforms help unify fragmented systems, simplify the use of complex RWD, and deliver actionable insights that accelerate trial planning and execution.